Healthcare & Pharmaceutical Market Research in Denmark

BioNixus is a leading healthcare market research company in Denmark, delivering Danish-language HCP surveys, KOL mapping, and payer landscape research aligned with DKMA, Medicinrådet (Danish Medicines Council), AMGROS hospital procurement, and Danish Regions requirements. BioNixus combines primary research depth with physician access across major Danish university hospitals and specialist networks.

A healthcare market research company in Denmark designs and executes studies covering physician prescribing behaviour, Medicinrådet HTA recommendation dynamics, AMGROS hospital medicine tender and formulary access, patient journeys, KOL influence mapping, and competitive landscape intelligence — for pharmaceutical, biotech, and medical device companies launching or growing in the Danish market.

Denmark operates a nationally administered public health system with 5 Danish Regions running hospital networks, a distinct hospital medicine access pathway through Medicinrådet HTA recommendations and AMGROS centralised procurement, and a primary care outpatient reimbursement system managed through Sygesikringen. Medicinrådet (est. 2017, replacing RADS) is unique among Nordic HTA bodies — making collective recommendations for all Danish hospital Regions. AMGROS operates as a pan-regional hospital medicine procurement agency with no direct equivalent in most European markets.

BioNixus covers oncology, immunology and biologics, cardiovascular, diabetes and metabolic (including GLP-1), rare disease, respiratory, infectious disease, neurology, medical devices, and consumer health across the Danish market — with Danish-language fieldwork capability across all 5 Danish regions.

Yes. BioNixus maintains physician and specialist networks across major Danish university hospitals including Rigshospitalet Copenhagen, Aarhus University Hospital, Odense University Hospital (OUH), Herlev Hospital, and Aalborg University Hospital. For scarce specialties such as oncology or rare disease, we recruit through Danish Cancer Society (Kræftens Bekæmpelse) networks, Danish Medical Association (Lægeforeningen) specialist directories, and Danish specialist society networks.

Focused Danish HCP surveys complete in 3–4 weeks. Full mixed-method programmes including Medicinrådet payer depth interviews and advisory board modules typically run 6–10 weeks depending on therapy area and respondent scarcity. Oncology and rare disease KOL programmes with multi-centre recruitment across Danish university hospitals may require extended planning timelines.

Yes. BioNixus designs and executes Danish patient research in compliance with GDPR and the Danish Data Protection Act (Databeskyttelsesloven). All patient and caregiver research involves documented informed consent, de-identified reporting, and secure data handling in accordance with Danish data privacy requirements.

Yes. Danish modules can run with comparable cells in Sweden, Norway, Finland, UK, Germany, France, and other European markets — using consistent instruments for portfolio committees managing multi-market access strategy from one research partner.